Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong interest in Phase III trials, potential partnerships, and a clear regulatory strategy for iopofosine I 131. Despite financial losses, the company has reduced expenses and extended its cash runway. The Q&A session reveals optimism about iopofosine's performance and market interest, with some uncertainties around data disclosure. Overall, the positive sentiment from partnerships and regulatory progress outweighs the financial concerns, suggesting a positive stock price movement.
Key Financial Performance
Cash and Cash Equivalents $13.2 million as of December 31, 2025, compared to $23.3 million as of December 31, 2024. The decrease was due to operational expenses, though $5.8 million was raised in the fourth quarter of 2025 to extend the cash runway.
Research and Development Expenses $11.5 million for Q4 2025 compared to $26.6 million for the year 2024. The decrease was driven by the conclusion of patient enrollment and declining patient follow-up for the CLOVER WaM clinical study, offset by increased preclinical development project costs.
General and Administrative Expenses $11.5 million for 2025 compared to $25.6 million for 2024. The decrease was primarily due to deemphasizing pre-commercialization efforts and related personnel cost reductions.
Other Income $1.1 million for 2025 compared to $7.3 million for 2024. The decrease was due to the impact of issuing and marking to market certain warrants, with 2025 warrants classified as permanent equity, reducing their impact on the statement of operations.
Net Loss $21.8 million for 2025 compared to $44.6 million for 2024. The reduction in net loss was attributed to lower R&D and SG&A expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
iopofosine I 131: Advanced regulatory alignment in Europe and the U.S. for Waldenström's Macroglobulinemia (WM). Conditional marketing authorization application planned for Q3 2026 in Europe, with potential commercialization in 2027. FDA breakthrough designation supports accelerated approval pathway in the U.S. Expanded addressable population in the U.S. with confirmatory study in post-BTKi-treated patients.
CLR 125: Initiated Phase Ib study for triple-negative breast cancer (TNBC). Early interim data expected in mid-2026.
CLR 225: Completed IND-enabling work for alpha-emitting asset targeting pancreatic cancer. Phase I trial initiation pending funding.
Global Intellectual Property Expansion: New patents issued across Europe, Asia Pacific, the Middle East, and the Americas, bolstering protection for iopofosine I 131, CLR-125, and the PDC platform.
Financial Position: Raised $15.2 million in 2025, extending cash runway into Q3 2026. Reduced R&D and SG&A expenses compared to 2024.
Supply Chain Strengthening: Established partnerships with ITM Technologies and Ionetix for commercial-scale access to Actinium-225 and Astatine-211.
Regulatory and Clinical Strategy: Clear regulatory paths established with EMA and FDA for iopofosine I 131. Plans to present 12-month follow-up data and other findings at major medical meetings in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Risks: The company is dependent on successful regulatory approvals in both the U.S. and Europe for iopofosine I 131. Any delays or failures in obtaining these approvals could significantly impact commercialization timelines and revenue generation. Additionally, the confirmatory Phase III trial required by the FDA introduces further risk, as its outcome is uncertain.
Financial Risks: The company ended 2025 with $13.2 million in cash and cash equivalents, which is only sufficient to fund operations into the third quarter of 2026. This creates a risk of financial instability if additional funding is not secured in a timely manner.
Pipeline Development Risks: The success of the pipeline, including CLR-125 and CLR-225, is contingent on positive clinical trial outcomes. Any unfavorable results or delays in these trials could hinder the company's ability to expand its product offerings and achieve strategic objectives.
Supply Chain Risks: The company relies on partnerships with ITM Technologies and Ionetix for the supply of critical isotopes like Actinium-225 and Astatine-211. Any disruptions in these supply chains could delay clinical development and commercialization efforts.
Market and Competitive Risks: The company faces competitive pressures in the oncology and radiopharmaceutical markets. Failure to demonstrate clear advantages over existing therapies could limit market adoption and revenue potential.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Regulatory and Commercialization Plans for Iopofosine I 131: Cellectar plans to submit a conditional marketing authorization application for iopofosine I 131 in Europe in Q3 2026, with potential approval and commercialization as early as 2027. In the U.S., the company is pursuing an NDA under the accelerated approval pathway, supported by FDA breakthrough designation and agency dialogue. A confirmatory Phase III trial is being designed to support full registration, targeting a post-BTKi-treated patient population in the second-line setting, which doubles the addressable market.
Pipeline Development and Clinical Trials: The Phase Ib study of CLR-125 in triple-negative breast cancer (TNBC) is ongoing, with early interim data expected in mid-2026. Additional sites will be added in Q2 2026. For CLR-225, IND-enabling work is complete, and a Phase I trial is ready to initiate pending funding. Preclinical studies in pancreatic cancer models have shown promising results.
Data Presentations and Regulatory Engagement: Cellectar plans to present 12-month follow-up data, including response rates, progression-free survival, and outcomes in patient subsets, at major medical meetings in 2026. These findings aim to support regulatory discussions and demonstrate the clinical benefit of iopofosine I 131.
Market Expansion and Strategic Partnerships: The company is engaging in global partnering discussions to support the iopofosine program. New supply partnerships with ITM Technologies and Ionetix ensure commercial-scale access to isotopes for CLR-225 development.
Intellectual Property and Financial Position: Cellectar expanded its global patent estate in 2025, providing long-term protection for its assets. The company raised $15.2 million in 2025, extending its cash runway into Q3 2026, enabling continued pipeline advancement and achievement of key milestones.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can the same package submitted to EMA be used for FDA submission, and how long after starting the Phase III trial can the FDA submission process be initiated?
A:Yes, the data itself is essentially the same, though there are some differences in subset analyses and package formatting between EMA and FDA. The FDA submission can be initiated about 1-2 months after the confirmatory study starts, with the expectation of enrolling 1-2 patients by then. The FDA review under the accelerated approval pathway would take 6 months, during which about 10% of patients should be enrolled.
Q:What are the differences in progression-free survival (PFS) between iopofosine and standard of care in the Phase III confirmatory study?
A:The median PFS for post-BTKi patients receiving standard salvage therapies is approximately 8 months. Iopofosine is expected to show more robust durability and better PFS, especially in earlier lines of therapy, based on updated 12-month data.
Q:Will the Phase III trial design include visual response rates before progression-free survival (PFS) data is available?
A:No, the primary endpoint is PFS, and secondary endpoints include response rates. Data from the confirmatory study will not be announced during enrollment to avoid bias.
Q:What is the expected enrollment speed and interest level for the Phase III trial in the U.S. and EU?
A:Physician interest is extremely high, with strong support from both thought leaders and community-based physicians. Patients are also expected to be highly engaged, especially after seeing the new data. The drug's ease of administration and significant need in the market are key factors driving interest.
Q:What are the plans for distribution in Europe, and what does the second-line patient population look like?
A:Cellectar plans to partner with other parties for commercialization in Europe. The European second-line patient population is slightly larger than the U.S., with over 12,000 patients. Initially, the drug will be approved for third-line or later use, transitioning to second-line after the confirmatory study.
Q:What is the benefit of the 12-month data compared to the December 2024 data?
A:The 12-month data includes follow-up for all patients, showing improvements in response rates, durability, and PFS compared to the December 2024 data. This data supports the regulatory pathway for accelerated approval and confirms better performance in earlier lines of therapy.
Q:Will the updated data include durability metrics such as progression-free survival (PFS) and duration of response (DOR)?
A:Yes, the updated data will include PFS and DOR metrics, along with response data such as major response rates and clinical benefit rates, for both the broader population and important subsets like post-BTKi patients.
Q:Review of Unclear Management Responses
A:Management avoided providing specific benchmarks or numerical expectations for iopofosine's performance in earlier lines of therapy compared to standard of care. They also did not disclose detailed 12-month data, citing that it has not been publicly released yet.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AACR Special
Actinium Astatine
Americas patent
Asia Pacific
Astatine development
Auger asset
Biosciences Full
CLOVER WaM
CLR phospholipid
Cellectar
Conference
PDC
Phase Ib
TNBC
addition
advancement
alignment
authorization application
dosing regimen
engagement
estate
expansion
finding
follow patient
income
isotope
milestone
month follow
protection iopofosine
registration
site
strength
study iopofosine
supply partnership
tumor inhibition
warrant
CLRB Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call presents a mixed outlook. While there are positive developments like the promising Phase II data for iopofosine and expanded partnerships, there are significant risks including financial sustainability concerns and regulatory approval uncertainties. The Q&A did not reveal any major concerns but highlighted the reliance on future milestones. The financials show decreased expenses but also a declining cash position. Without a clear market cap, the reaction is uncertain, but the mixed signals suggest a neutral impact on stock price.
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights strong interest in Phase III trials, potential partnerships, and a clear regulatory strategy for iopofosine I 131. Despite financial losses, the company has reduced expenses and extended its cash runway. The Q&A session reveals optimism about iopofosine's performance and market interest, with some uncertainties around data disclosure. Overall, the positive sentiment from partnerships and regulatory progress outweighs the financial concerns, suggesting a positive stock price movement.
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed outlook. While there are positive developments such as decreased expenses and strong partnership momentum, significant risks persist, including reliance on rare isotopes and funding needs for trials. The Q&A reveals cautious optimism but lacks concrete guidance and pricing details, which may concern investors. Given the balanced nature of positive and negative factors, a neutral stock price reaction is expected.
Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript
Unknown8-14
While there are positive aspects, such as reduced R&D expenses and a strategic plan for accelerated approval, significant risks are present. Funding challenges and regulatory uncertainties are major concerns, as the company's plans hinge on securing additional capital. The Q&A reveals management's lack of clarity on critical timelines, further increasing uncertainty. The decrease in cash reserves and increased net loss also contribute to a negative outlook. Without a market cap, we assume mid-cap, leading to a likely stock price decrease of -2% to -8%.
CLRB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
